Related Experiment Video

Updated: Oct 3, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Susceptibility Modules and Genes in Hypertrophic Cardiomyopathy by WGCNA and ceRNA Network Analysis

Yifan Sun1, Zhongbo Xiao1, Yequn Chen1

  • 1Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, China.

Frontiers in Cell and Developmental Biology
|February 18, 2022
PubMed

Insights

Researchers identified a regulatory network and hub gene, Insulin-like Growth Factor Binding Protein 5 (IGFBP5), in Hypertrophic Cardiomyopathy (HCM). This discovery offers potential molecular mechanisms for HCM diagnosis and treatment.

Area of Science:

  • Genomics
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Hypertrophic Cardiomyopathy (HCM) is a complex genetic heart disease.
  • Identifying regulatory networks and key genes is crucial for understanding HCM pathogenesis.

Purpose of the Study:

  • To identify a competing endogenous RNA (ceRNA) network in HCM.
  • To pinpoint a hub gene involved in HCM progression.

Main Methods:

  • Utilized microarray datasets from NCBI GEO database.
  • Applied R package 'limma' for differential gene expression analysis.
  • Constructed ceRNA networks using online databases and WGCNA.
  • Performed Gene Set Enrichment Analysis (GSEA) for functional annotation.

Main Results:

  • Identified 269 differentially expressed lncRNAs, 63 miRNAs, and 879 mRNAs.
  • Discovered specific miRNA-lncRNA-mRNA interactions potentially regulating HCM.
  • Identified Insulin-like Growth Factor Binding Protein 5 (IGFBP5) as a key hub gene.
  • GSEA indicated IGFBP5's role in myosin complex synthesis and actin cytoskeleton regulation.

Conclusions:

  • The study proposes a molecular regulatory mechanism for HCM.
  • IGFBP5 may play a significant role in the development and progression of HCM.
  • Findings offer potential targets for HCM diagnosis and therapy.

Keywords:
IGFBP5bioinformaticscompeting endogenous RNA networkhypertrophic cardiomyopathyweighted correlation network analysis

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.5K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
101
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
50
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77